Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Bacteriophages of the Human Virome01:23

Bacteriophages of the Human Virome

Bacteriophages are found throughout the human body. They may even outnumber eukaryotic viruses, forming an important and dynamic component of the human virome. Indeed, phages represent the most abundant viral entities, with densities in the gut reaching up to 10⁹ particles per gram of fecal matter, and many belonging to orders such as Caudovirales and Microviridae, while a substantial proportion remains unclassified as viral “dark matter.”Lysogeny and Genetic ExchangeIn the gut, bacteriophages...
Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...
DNA Bacteriophages01:26

DNA Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...
Viral Replication: Lysogenic Cycle01:16

Viral Replication: Lysogenic Cycle

The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protecting Newborns from Multidrug-Resistant Infections: The Emerging Role of Bacteriophages.

Viruses·2026
Same author

When bacteriophages encounter macrophages during their journey through the human body.

Frontiers in cellular and infection microbiology·2026
Same author

Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.

Clinical microbiology reviews·2026
Same author

Enterobacter-specific bacteriophages Entb_43 and Entb_45 interact with the intestinal epithelium to limit intracellular infection and may undergo partial translocation.

Microbial pathogenesis·2026
Same author

Disruption of the SAGA CORE triggers collateral degradation of KAT2A.

Nature communications·2026

Related Experiment Video

Updated: Jun 13, 2026

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics
09:23

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Surveys on phage therapy: Current understanding and practical implications.

Maciej Żaczek1, Andrzej Górski2, Beata Weber-Dąbrowska3

  • 1Bacteriophage Laboratory, Phage Therapy Department, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

International Journal of Antimicrobial Agents
|June 11, 2026
PubMed
Summary

Phage therapy awareness is growing among physicians globally, highlighting the urgent need to combat antibiotic resistance. However, slow progress on regulatory and clinical trial challenges hinders its widespread adoption.

Keywords:
Antibiotic resistanceClinician attitudesPhage therapyPublic perceptionSurveys

More Related Videos

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo
08:46

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo

Published on: January 26, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics
09:23

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo
08:46

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo

Published on: January 26, 2024

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Phage therapy is gaining traction globally as a potential solution to antibiotic resistance.
  • Physician surveys indicate increasing awareness and a perceived clinical need for phage treatment.

Purpose of the Study:

  • To evaluate if medical and patient communities' readiness and knowledge align with the scientific advancement of phage therapy.
  • To assess the current state of phage therapy adoption and identify barriers to its expansion.

Main Methods:

  • Review of recent global physician surveys on phage therapy awareness and willingness to use.
  • Analysis of existing literature on regulatory hurdles, clinical trial data, and industry support for phage therapy.

Main Results:

  • Surveys consistently show growing awareness and recognition of the urgency to use phage therapy against antibiotic resistance.
  • Significant obstacles remain, including regulatory uncertainties, limited treatment centers, and insufficient robust clinical trial evidence.

Conclusions:

  • While awareness of phage therapy is increasing, its expansion beyond compassionate use is hampered by slow progress in addressing key challenges.
  • Further research and coordinated efforts are needed to bridge the gap between scientific progress and clinical implementation of phage therapy.